medric medric
[닫기]
잠시만 기다려 주세요. 로딩중입니다.

Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Korean Journal of Internal Medicine 2019년 34권 5호 p.1107 ~ 1115
 ( Kim Moon-Jin ) - Myongji Hospital Department of Internal Medicine

 ( Kim Sung-Min ) - Sungkyunkwan University School of Medicine Samsung Changwon Hospital Department of Medicine
 ( Jung Hyun-Ae ) - Hallym University Dongtan Sacred Heart Hospital Department of Internal Medicine
 ( Hong Jung-Yong ) - University of Ulsan College of Medicine Asan Medical Center Department of Oncology
 ( Chang Won-Jin ) - Korea University College of Medicine Department of Internal Medicine
 ( Choi Moon-Ki ) - National Cancer Center Center for Colorectal Cancer
 ( Kim Hye-Sook ) - Sungkyunkwan University School of Medicine Samsung Changwon Hospital Department of Medicine
 ( Sun Jong-Mu ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Medicine
 ( Park Keun-Chil ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Medicine
 ( Ahn Myung-Ju ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Medicine

Abstract


Background/Aims: We investigated the efficacy and toxicity of a weekly schedule of docetaxel and cisplatin as a first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Methods: In this study, 18 patients with previously diagnosed R/M HNSCC were treated with combination chemotherapy of weekly docetaxel 35 mg/m2 (day 1 and 8) and cisplatin 70 mg/m2 (day 1) as first-line chemotherapy, repeated every 3 weeks.

Results: Partial response and stable disease were observed in six patients (33.3%; 95% confidence interval [CI], 11.1% to 55.6%) and six patients (33.3%; 95% CI, 11.1% to 55.6%), respectively. The median overall survival and progression-free survival were 11.26 months (95% CI, 8.87 to 15.83) and 5.68 months (95% CI, 4.80 to 6.51), respectively. The major toxicity was grade 1/2 anemia (50%). Grade 3/4 neutropenia was observed in one patient (5.6%). Among the non-hematologic toxicities, grade 1/2 hepatotoxicity was most common (22.2%), and grade 3/4 infection was observed in one patient (5.6%). There was no treatment-related mortality.

Conclusions: For patients with R/M HNSCC, a cisplatin and weekly docetaxel regimen showed high efficacy with tolerable toxicity as a first-line treatment.

키워드

Cisplatin; Docetaxel; Head and neck neoplasms; Carcinoma, squamous cell
원문 및 링크아웃 정보
  
등재저널 정보
SCI(E)
MEDLINE
KCI
KoreaMed
KAMS